Proton therapy is used today to treat many cancers and is particularly appropriate in situations where surgery options are limited, and conventional radiotherapy presents unacceptable risks to patients. A few years ago, it was suggested that an increase of up to a factor of two of the doses at the proton Bragg peak could be achieved if boron is accumulated in the tumor tissues. The mechanism responsible for a higher dose was suggested to be related to proton-boron fusion reactions, leading to the production of high Linear Energy Transfer (LET) α-particles. Nowadays there are single works showing the effectiveness of proton beam irradiation boron-11-containing cancer cells. A limited number of the studies devoted to the application of 11B(p,3a) nuclear reaction in proton therapy and lack of consistency in their results do not allow to judge about the prospects of the boron-containing drugs utilization in proton therapy to increase its antitumor efficacy. In this work, we experimentally test the possibility to enhance proton biological effectiveness in boron-11-containing cancer cells in vitro. Human glioblastoma cells were pre-incubated with boron compound (Na₂B ₄O₇, sodium tetraborate) and irradiated with increasing doses 2-8 Gy at the proton Bragg peak. To test whether the physical nuclear reaction 11B(p,3a) results in an enhancement of the cancer cell death by high-energy proton beam irradiation, cell lines were also irradiated with graded doses 2-8 Gy using
γ-ray source. The ability of boron compound to activate the cancer cell death with protons at the Bragg peak irradiation was shown in vitro. At the same time, weaker similar effect was determined for gamma-irradiation that may indicate not only the physical nature of influence boron at irradiated cancer cell viability but a specific biological effect. The data suggest that the combined effect of proton therapy with ¹¹B on glioma cells increases their sensitivity to proton irradiation with low toxicity of the boron compound for cells of normal morphology.

1. R. Mohan, D. Grosshans, “Proton therapy – present and future,” Adv. Drug Delivery Rev., vol. 109, pp. 26–44, Jan. 2017.
   DOI: 10.1016/j.addr.2016.11.006
2. X. Tian, K. Liu, Y. Hou, J Cheng, J. Zhang, “The evolution of proton beam therapy: Current and future status,” Mol. Clin. Oncol., vol. 8, no. 1, pp. 15-21, Jan. 2018.
   DOI: 10.3892/mco.2017.1499
3. A. C. Begg, F. A. Stewart, C. Vens, “Strategies to improve radiotherapy with targeted drugs,” Nat. Rev. Cancer, vol. 11, no. 4, pp. 239-253, Apr. 2011.
   DOI: 10.1038/nrc3007
   PMid: 21430696
4. F. Tranquart, “Radiosensitizers and radiochemotherapy in the treatment of cancer,” Ultrasound in Medicine & Biology, vol. 42, no. 2, Nov. 2015.
   DOI: 10.1016/j.ultrasmedbio.2015.10.004
5. A. A. Lipengol’ts, A. A. Cherepanov, V. N. Kulakov, E. Yu. Grigor’eva, I. B. Merkulova, I. N. Sheino, “Comparison of the antitumor efficacy of bismuth and gadolinium as dose-enhancing agents in formulations for photon capture therapy,” Pharm. Chem., vol. 51, pp. 783–786, Dec. 2017.
   DOI: 10.1007/s11094-017-1693-1
6. I. N. Sheino, P. V. Izhevskij, A. A. Lipengolts, V. N. Kulakov, A. A. Wagner, E. S. Sukhikh et al., “Development of binary technologies of radiotherapy of malignant neoplasms: condition and problems,” Bulletin of Siberian Medicine, vol. 16, no. 3, pp. 192-209, 2017.
   DOI: 10.20538/1682-0363-2017-3-192-209
7. S. Miyatake, M. Wanibuchi, N. Hu, K. Ono, “Boron neutron capture therapy for malignant brain tumors,” J. Neurooncol., vol. 149, no. 1, pp. 1–11, Aug. 2020.
   DOI: 10.1007/s11060-020-03586-6
8. D. Yoon, J. Jung, T. Suh, “Application of proton boron fusion reaction to radiation therapy: A Monte Carlo simulation study,” Appl. Phys. Lett., vol. 105, p. 223507, Dec. 2014.
   DOI: 10.1063/1.4903345
9. J. Y. Jung, D. K. Yoon, B. Barraclough, H. C. Lee, T. S. Suh, B. Lu, “Comparison between proton boron fusion therapy (PBFT) and boron neutron capture therapy (BNCT): Monte Carlo study,” Oncotarget., vol. 8, no. 24, pp. 39774-39781, Feb. 2017.
   DOI: 10.18632/oncotarget.15700
10. G. A. P. Cirrone, L. Manti, D. Margarone, G. Petringa, L. Giuffrida, A. Minopoli et al., “First experimental proof of proton boron capture therapy (PBCT) to enhance proton therapy effectiveness,” Sci. Rep., vol. 8, no. 1, p. 1141, Jan. 2018.
    DOI: 10.1038/s41598-018-19258-5
11. A. Mazzone, P. Finocchiaro, S. Lo Meo, N. Colonna, “On the (un) effectiveness of proton boron capture in proton therapy,” Eur. Phys. J. Plus, vol. 134, p. 361, Jul. 2019.
    DOI: 10.1140/epjp/i2019-12725-8
12. A. Volnitskiy, T. Shtam, V. Burdakov, R. Kovalev, A. Konev, M. Filatov, “Abnormal activity of transcription factors gli in high-grade gliomas,” PLoS One, vol. 14, no. 2, pp. e0211980, Feb. 2019.
    DOI: 10.1371/journal.pone.0211980
    PMid: 30730955
    PMCid: PMC6366868
13. S.A. Artamonov, E.M. Ivanov, N.A. Ivanov, J.S. Lebedeva, G. A. Riabov. “Numerical simulation and optimization of the variable energy 60–1000 MeV proton beams at PNPI synchrocyclotron for testing the radiation resistance of electronics,” Phys. Part. Nuclei Lett., vol. 14, pp. 188–200, Jan. 2017.
    DOI: 10.1134/S1547477117010046
14. A. Yu. Bushmanov, I. N. Sheino, A. A. Lipengolts, A. N. Solovev, S. N. Koryakin, “Prospects of proton therapy combined technologies in the treatment of cancer,” Medical Radiology and Radiation Safety, vol. 64, no. 3, pp. 8-11, 2019.
    DOI: 10.1371/journal.pone.0211980

Dmitry Lebedev, Luiza Garaeva, Vladimir Burdakov, Andrey Volnitskiy, Natalya Razgildina, Alina Garina, Dmitry Amerkanov, Fedor Pack, Konstantin Shabalin, Evgeniy Ivanov, Victor Ezhov, Andrey Konevega, Tatiana Shtam,"Radiosensitizing effect of boron enhances the effectiveness of proton therapy in vitro," RAD Conf. Proc, vol. 4, 2020, pp. 60–65, http://doi.org/10.21175/RadProc.2020.12